Features | Partner Sites | Information | LinkXpress
Sign In
JIB
GLOBETECH PUBLISHING
GLOBETECH PUBLISHING

New Lab Technology Will Boost Cell Therapy Applications

By BiotechDaily International staff writers
Posted on 25 Nov 2013
Image: The Xuri Cell Expansion System W25 (Photo courtesy of GE Healthcare).
Image: The Xuri Cell Expansion System W25 (Photo courtesy of GE Healthcare).
A newly released family of cell culture systems was designed specifically to support and advance the growing field of cell therapy.

The Xuri Cell Expansion System W25 is the first member of GE Healthcare's (Chalfont St. Giles, United Kingdom) new hi-tech cell culture systems to be released for sale.

This system comprises a reliable and intuitive device for expansion of human cell cultures for cellular therapy purposes. It employs single-use, functionally closed disposables to minimize risk of contamination. The Xuri system can accommodate working volumes from as little as one liter—appropriate for growing high-density cell cultures—with room to expand up to 25 liters. The system is based on GE Healthcare's WAVE rocking technology that provides mixing and aeration. The Xuri system is functionally closed, which minimizes the risk of cell contamination while allowing the culture to reach high cell densities.

The Xuri Cell Expansion System W25 is enhanced by sensors to monitor the cell culture environment and is operated via "UNICORN" control software. The system was designed to deliver reliable and accurate performance for research, process development, or manufacturing operations.

Eric Roman, general manager of research and applied markets at GE Healthcare, said, “Through our scale and innovation, we are committed to addressing the significant challenges that remain in moving from highly promising experimental cell therapies to widely available and affordable treatments. We have an extensive research program, working with leaders in the field such as the Karolinska University Hospital, (Stockholm, Sweden) to develop tailored technologies and workflows. The focus of our Xuri technology family is to enable the safe, reliable, and efficient progress of cell therapies from clinical development to commercialization.”

Related Links:

GE Healthcare
Karolinska University Hospital



comments powered by Disqus

Channels

Genomics/Proteomics

view channel
Image: Alternative splicing produces two protein isoforms (Photo courtesy of Wikimedia Commons).

Key Regulator of Cancer-Inducing Alternative Splicing Identified

Cancer researchers have identified the splicing factor RBM4 (RNA-binding protein 4) as a key determinant in processes that prevent tumor development and spread. RBM4 is known to be crucial to gene splicing... Read more

Drug Discovery

view channel

Ibuprofen May Restore Immune Function in Older Individuals

New research suggests that macrophages from the lungs of old mice respond differently to infections than those of young mice, and ibuprofen given to the mice reversed these changes. New research using lab mice suggests that the solution to more youthful immune function might already be a common over-the-counter pain reliever.... Read more

Therapeutics

view channel
Image: Hair follicle (blue) being attacked by T cells (green) (Photo courtesy of Christiano Lab/Columbia University Medical Center).

Hair Restoration Method Clones Patients’ Cells to Grow New Hair Follicles

Researchers have developed of a new hair restoration approach that uses a patient’s cells to grow new hair follicles. In addition, the [US] Food and Drugs Administration (FDA) recently approved a new drug... Read more

Business

view channel

Partnership Established to Decode Bowel Disease

23andMe (Mountain View, CA,USA), a personal genetics company, is collaborating with Pfizer, Inc. (New York, NY, USA), in which the companies will seek to enroll 10,000 people with inflammatory bowel disease (IBD) in a research project designed to explore the genetic factors associated with the onset, progression, severity,... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.